Frenel JS - Search Results

1

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.

Domergue C, Martin E, Lemarié C, Jézéquel P, Frenel JS, Augereau P, Campone M, Patsouris A. Domergue C, et al. Among authors: frenel js. Cancers (Basel). 2022 May 19;14(10):2509. doi: 10.3390/cancers14102509. Cancers (Basel). 2022. PMID: 35626113 Free PMC article.

2

Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: a decline since 2003.

Fontenoy AM, Leux C, Delacour-Billon S, Allioux C, Frenel JS, Campone M, Molinié F. Fontenoy AM, et al. Among authors: frenel js. Cancer Epidemiol. 2010 Jun;34(3):238-43. doi: 10.1016/j.canep.2010.03.007. Epub 2010 Apr 20. Cancer Epidemiol. 2010. PMID: 20409772

3

[Her2 positive breast cancer: practices].

Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS. Campone M, et al. Among authors: frenel js. Bull Cancer. 2011 Feb;98(2):154-63. Bull Cancer. 2011. PMID: 21591301 Free article. Review. French.

4

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M. Gourmelon C, et al. Among authors: frenel js. Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Expert Opin Pharmacother. 2011. PMID: 22087618 Review.

5

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Gourmelon C, Frenel JS, Campone M. Gourmelon C, et al. Among authors: frenel js. Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167. Expert Rev Anticancer Ther. 2012. PMID: 22316367 Review.

6

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG. Loussouarn D, et al. Among authors: frenel js. Int J Oncol. 2012 Jun;40(6):2058-62. doi: 10.3892/ijo.2012.1404. Epub 2012 Mar 16. Int J Oncol. 2012. PMID: 22447191

7

[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

Campone M, Frenel JS, André F, Bachelot T, Juin P. Campone M, et al. Among authors: frenel js. Bull Cancer. 2012 Jun;99(6):665-72. doi: 10.1684/bdc.2012.1591. Bull Cancer. 2012. PMID: 22614782 Free article. Review. French.

8

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses.

Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M. Jézéquel P, et al. Among authors: frenel js. Database (Oxford). 2013 Jan 15;2013:bas060. doi: 10.1093/database/bas060. Print 2013. Database (Oxford). 2013. PMID: 23325629 Free PMC article.

9

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M. Frenel JS, et al. J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17. J Neurooncol. 2013. PMID: 23681562

10

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC. Awada A, et al. Among authors: frenel js. Anticancer Drugs. 2016 Apr;27(4):342-8. doi: 10.1097/CAD.0000000000000336. Anticancer Drugs. 2016. PMID: 26796987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page